WHO Committee Adopts Weakened Draft Resolution On Drug Pricing Transparency

Reuters: WHO agrees watered-down resolution on transparency in drug costs
“World Health Organization members agreed on Tuesday to push for clearer drug pricing but stepped back from proposals by activists to force pharmaceutical firms to disclose the cost of making medicines. … An earlier draft of the text would have given the WHO explicit powers to collect and analyze data on procurement prices and costs from clinical trials. But that wording was omitted from a draft published on Tuesday. A WHO committee adopted the draft by consensus after a long negotiation, just in time for it to be considered by the WHO’s annual assembly which was due to close later on Tuesday…” (Miles, 5/28).

Additional coverage of negotiations on the resolution is available from CBC News, Health-e News, and Health Policy Watch (2).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.